Cargando…

Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study

Migraine is underpinned by central nervous system neuroplastic alterations thought to be caused by the repetitive peripheral afferent barrage the brain receives during the headache phase (cortical hyperexcitability). Calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAbs) are highly e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szabo, Edina, Ashina, Sait, Melo-Carrillo, Agustin, Bolo, Nicolas R., Borsook, David, Burstein, Rami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623369/ https://www.ncbi.nlm.nih.gov/pubmed/37866119 http://dx.doi.org/10.1016/j.nicl.2023.103531

Ejemplares similares

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Narrow band green light effects on headache, photophobia, sleep, and anxiety among migraine patients: an open-label study conducted online using daily headache diary
por: Lipton, Richard B., et al.
Publicado: (2023)

Responsivity of Periaqueductal Gray Connectivity Is Related to Headache Frequency in Episodic Migraine
por: Solstrand Dahlberg, Linda, et al.
Publicado: (2018)

Ictal and interictal brain activation in episodic migraine: Neural basis for extent of allodynia
por: Maleki, Nasim, et al.
Publicado: (2021)

Psychotherapy Treatment of Generalized Anxiety Disorder Improves When Conducted Under Narrow Band Green Light
por: Melo-Carrillo, Agustin, et al.
Publicado: (2023)

Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats
por: Melo-Carrillo, Agustin, et al.
Publicado: (2019)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood–brain barrier
por: Melo-Carrillo, Agustin, et al.
Publicado: (2021)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

Primary Somatosensory Cortices Contain Altered Patterns of Regional Cerebral Blood Flow in the Interictal Phase of Migraine
por: Hodkinson, Duncan J., et al.
Publicado: (2015)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Cortico–Cortical Connections of Primary Sensory Areas and Associated Symptoms in Migraine
por: Hodkinson, Duncan J., et al.
Publicado: (2017)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety
por: Noseda, Rodrigo, et al.
Publicado: (2014)

Altered Hypothalamic Functional Connectivity with Autonomic Circuits and the Locus Coeruleus in Migraine
por: Moulton, Eric A., et al.
Publicado: (2014)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Migraine attacks the Basal Ganglia
por: Maleki, Nasim, et al.
Publicado: (2011)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q003sbpcompppu6kvf3e075cl4